Jefferies Raises Price Target on Chemours (CC) to $17; Reiterates Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
The Chemours Company Reports Third Quarter 2016 Results; Significant Earnings and Margins Increases Driven by Progress on Transformation Plan and Improved Market Conditions
November 6, 2016 4:30 PM ESTWILMINGTON, Del., Nov. 6, 2016 /PRNewswire/ --
Third Quarter 2016 Highlights
Net Sales of $1.4 billion Net Income of $204 million, or $1.11 per diluted share, including gain on asset sales of $169 million, impairment charges of $46 million, interest expense of $51 million and restructuring costs of $14 million Adjusted EBITDA of $268 million Adjusted Net Income of $112 million, or $0.61 per diluted shareOther Highlights
Continued progress on all transformation plan objectives, including cost reductions, growth initiatives and portfolio rationalization Improved cash from operating activities by ~$440 million year-to-date Retired $315 million of long term... More